BNT162b2 mRNA COVID-19 vaccine and booster in patients with autoimmune rheumatic diseases: a national cohort study.
Amir BieberIftach SagyLena NovackShay BrikmanRan AbuhasiraSnait AyalonIrina NovofastovskiMahmoud Abu-ShakraReuven MaderPublished in: Annals of the rheumatic diseases (2022)
Our results indicate that both the BNT162b2 mRNA COVID-19 vaccine and the booster are associated with better COVID-19 outcomes in patients with ARD.